2025
Nordyke RJ , Patterson JA, Motyka J, March B, Kirson NY, Long G. 2025. The impact of the Inflation Reduction Act’s drug price negotiation program on incentives for clinical development of new drugs. Value Health 28(12)1881-1889; doi: 10.1016/j.jval.2025.08.011 . PMID: 40902797.
View Abstract
Publication: Manuscripts
Patterson JA, Motyka J, Salih R, Nordyke RJ , O’Brien JM, Campbell JD. 2025. Subsequent indications in oncology drugs: Pathways, timelines, and the Inflation Reduction Act. Ther Innov Regul Sci 59(1):102-111; doi: 10.1007/s43441-024-00706-6 . PMID: 39369117.
View Abstract
Publication: Manuscripts
2024
Wagner TD, Westrich KD, Nordyke RJ , Campbell JD. 2024. Inflation-adjusted analysis of ICER’s Unsupported Price Increase reports: Contextualizing drug spending changes. J Med Econ 27(1):1537-1541; doi: 10.1080/13696998.2024.2428109 . PMID: 39626873.
View Abstract
Publication: Manuscripts
2018
Fryzek J, Reichert H , Summers N, Townes L, Deuson R, Alexander DD, Vanderpuye-Orgle J. 2018. Indirect treatment comparison of cabazitaxel for patients with metastatic castration-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen. PLoS One 13(4):e0195790; doi: 10.1371/journal.pone.0195790 . PMID: 29641566.
View Abstract
Publication: Manuscripts
2012
Wang A, Halbert RJ, Baerwaldt T, Nordyke RJ . 2012. U.S. payer perspectives on evidence for formulary decision-making. J Oncol Pract 8(3 Suppl):22s-27s; doi: 10.1200/JOP.2011.000526 . PMID: 22942820.
View Abstract
A Division of
